



2013 FINANCIAL REPORT



Contents

<i>Introduction</i>	3
<i>Financial Performance 2011-2013</i>	4
<i>2013 Financial Performance</i>	6
<i>Management of Conflict of Interest</i>	8
<i>Working in Partnership</i>	9
<i>Report of The Auditor on the 2013 Financial Statements</i>	13
<i>UICC Partners</i>	15

INTRODUCTION



We are pleased to release the first ever UICC Financial Report. In previous years, the financial performance of UICC has been reported in the Annual Report of that year. However, this year and from now on, we will provide a more comprehensive and detailed separate review of our financial performance, highlighting results over a three year period so that you can see progress in the financial management of the organisation.

This change has been prompted by our continued commitment to operate in a transparent and open way so that our members, partners and those who work with us on a day-to-day basis receive detailed information on the way in which UICC is funded and how it uses those funds across its core operational activities.

The purpose of UICC is to 'unite the cancer community to reduce the global cancer burden, to promote greater equity, and to integrate cancer control into the world health and development agenda'; and to achieve this, we focus on three interlinked activities: advocacy, convening and running global capacity building projects. Our outputs under each of these themes have been captured within the body of the 2013 Annual Report, which I encourage you to read (see www.uicc.org/annual-report-2013). It describes the depth and breadth of the work which we undertake on behalf of, and in collaboration with, our members.

Over the last three years, UICC has increased its membership base from 465 to 815 organisations. During that time we also increased the number of funding partners we have from 23 to 47, each of which contribute significantly through funds or in-kind support to the work of UICC. We now have 28 corporate partners, an increase of 11 since the end of 2011. Nineteen of our members have also become partners and work with the UICC team to support and help deliver our core activities. A full list of our partners and the level of their funding contribution to UICC is shown on page 15 of this report. This growth has been accommodated with a stable staff base of only 27 full time equivalent staff throughout the three years.

At the end of 2013, we closed our first three-year fundraising campaign 'Together we are Stronger' which raised USD 8 million in funds and future commitments to our work. To sustain the next phase of UICC's plans, a new three-year campaign entitled 'Together for Action' was launched on World Cancer Day 2014 with a three-year funding goal of USD 20 million and we are confident that we will achieve this ambitious target.

In 2013 we delivered our business activities in-line with the annual forecast budget. Our income was sufficient to cover expenses and we managed a year of good financial management, concluding with a balanced budget.

Once again, we received a clean annual audit from our auditors PricewaterhouseCoopers. We have included their audit letter on page 13 of this report. I consider this to be a significant achievement given that we have also transitioned our accounting base for all our activities from Swiss Franc (CHF) to US Dollar (USD) and have taken the necessary steps in 2014 to adopt a more robust accounting standard, Swiss GAAP FER 21, which is specifically tailored to not-for-profit organisations.

In addition to running our own finances, UICC continues to be the fiscal agent for the NCD Alliance (see www.ncdalliance.org). I am pleased to report that the NCD Alliance also had a very successful 2013 and ended the year in a stronger financial position than previously, carrying through an improved reserve position into 2014. Changes to the funding model of the NCD Alliance, with each signatory of the memorandum of understanding contributing to the on-going core operating costs, will give the NCD Alliance a sound financial base for future years.


I hope that you find this new UICC Financial Report of interest and that you appreciate the information presented. We are deeply proud of the way in which UICC has matured in the last few years, and the financial results bare witness to that progress.

Cary Adams
Chief Executive Officer
Union for International Cancer Control (UICC)

FINANCIAL PERFORMANCE 2011-2013

The chart below shows the total income UICC received for the years 2011, 2012 and 2013. We have seen a steady growth over the period from USD 7.4m in 2011 to USD 10.5m in 2013. We received approximately USD 3.3m per year from our membership - a combination of membership fees and additional contributions to support our core activities and project work. Annual funding from our corporate partners has increased from USD 1.1m in 2011 to nearly USD 1.5m in 2013. Additionally, the royalties received from our scientific publications exceeded USD 3m during this period.

TOTAL INCOME 2011-2013 USD 26.4m



"We really appreciate the way in which UICC is transparent in regards to how they operate financially and in the context of conflict of interest. The strategy and plans of UICC are clear and our involvement as a partner supports these and meets our own international objectives."

Anne Lise Ryel,
Chief Executive Officer,
Norwegian Cancer Society


60% of total income received was restricted and allocated to specific projects and activities, with the other 40% of unrestricted income for general organisational support. 64% of the income received from corporate partners has been unrestricted.

Expenditure for the same period has been in-line with annual income, albeit in 2013 we benefited from a legacy donation of USD 2.7m, a proportion of which has been earmarked for training and education activities if and when we identify appropriate investment opportunities.


We have maintained a steady level of reserves to cover six months of operating costs at all times and our hedging policy has sheltered us from exchange rate fluctuations between the US Dollar (in which we receive the majority of our income) and Swiss Franc (in which we have the majority of our costs).

Of our total organisational expenditure 2011-2013 of USD 24.5m, (and on a fully cost allocated basis), we spent approximately 10% on advocacy, 30% on our convening activities (World Cancer Day, World Cancer Congress and the World Cancer Leaders' Summit) and the remainder on our core capacity building projects. Please refer to the UICC 2013 Annual Report to understand the nature of our activities in these areas.

TOTAL EXPENDITURE 2011-2013 USD 24.5m



CAPACITY BUILDING EXPENDITURES 2011-2013 USD 12.2M



Specifically, we have spent more than USD 12m in the last three years on our capacity building projects such as Global Access to Pain Relief (GAPRI), Childhood Cancer (ChiCa), Global Initiative for Cancer Registries (GICR), Cervical Cancer Initiative (CCI), Fellowships, TNM, Globalink and our new International Cancer Control Partnership (ICCP) portal. The pie chart above shows the breakdown of this spend on a fully-allocated basis for the period 2011-2013.

We are pleased with the way in which the funding base has developed in the last three years. More organisations commit more funds to UICC over a longer planning period. This provides stability for the organisation and allows us to plan towards a three-year horizon with confidence. We anticipate this trend to continue in the coming years.

2013 FINANCIAL PERFORMANCE

We maintained a sound financial position during the last reporting year. The total organisational expenses in 2013 of USD 8.1 million* were fully covered by funds available. The financial year closed with a balanced, unrestricted operating result, a detailed breakdown of which is shown on the following page.

Income from grants and other designated contributions for specific activities undertaken by UICC represented the majority of the total income. Other revenues were primarily derived from member fees, corporate partner unrestricted contributions and income from scientific publications. We closed 2013 in a healthy financial position with current reserves covering six months of core operating costs.

UICC continued to assume the responsibility for the financial management of the NCD Alliance, which had expenditure of USD 730k in 2013 and was covered by an income of USD 1.27m. The balance being taken forward to cover planned activities in 2014 is detailed in the NCD Alliance Business Plan. Note that the NCD Alliance figures are included in the financial statements of UICC.

The Finance Committee of the Board of Directors, chaired by the UICC Treasurer, Greg Bontrager, from the American Cancer Society, provides oversight of UICC's finances working closely with senior management. UICC's financial statements for 2013 and internal control systems have been audited by PricewaterhouseCoopers.

* This figure excludes NCD Alliance expenses booked through UICC

2013 INCOME AND EXPENDITURE VS 2012 INCOME AND EXPENDITURE (IN US DOLLARS)

	2013			2012		
	Unrestricted	Restricted	Total	Unrestricted	Restricted	Total
INCOME						
Contributions and Grants	3,395	6,957,344	6,960,739	11,579	5,247,865	5,259,443
Membership Dues and Contributions	1,180,017		1,180,017	1,189,462		1,189,462
Corporate Partners	1,067,235		1,067,235	795,106		795,106
Publications	1,135,845		1,135,845	1,103,535		1,103,535
NCD Alliance		1,273,097	1,273,097		439,024	439,024
Other	157,811	1,300	159,111	160,561	1,965	162,526
TOTAL INCOME	3,544,303	8,231,741	11,776,044	3,260,244	5,688,854	8,949,097
EXPENDITURES						
Projects and Initiatives	4,501	3,121,382	3,125,883		3,074,564	3,074,564
UICC Congresses		1,536,996	1,536,996		2,380,518	2,380,518
Operating Costs	3,497,311		3,497,311	3,245,694		3,245,694
NCD Alliance		732,189	732,189		720,149	720,149
TOTAL EXPENDITURE	3,501,812	5,390,567	8,892,380	3,245,694	6,175,231	9,420,925
Income over (under) expenditure	42,491	2,841,174	2,883,665	14,550	(486,377)	(471,826)
FUND BALANCES - Beginning of year	2,558,247	2,453,634	5,011,881	2,480,894	2,940,010	5,420,905
FUND BALANCES - End of year	2,668,637	5,294,808	7,963,445	2,558,247	2,453,634	5,011,881

2013 BALANCE SHEET VS 2012 BALANCE SHEET

	2013	2012
ASSETS		
Current accounts	3,941,054	2,012,593
Deposits and Financial investments	4,079,003	3,499,698
Membership dues, net	-	8,212
Other receivables	152,620	123,504
Prepaid expenses	79,399	2,963
Total current assets	8,252,076	5,646,970
Fixed assets, net	53,151	63,621
Total non current assets	53,151	63,621
TOTAL	8,305,227	5,710,591
LIABILITIES		
Accounts payable and accrued expenses	326,030	675,622
Other liabilities	15,752	23,088
Total current liabilities	341,782	698,710
Trust Funds - restricted	5,294,808	2,453,634
Fund balance - unrestricted	1,655,038	1,612,547
Statutory reserve - unrestricted	500,000	500,000
Translation differences	513,600	445,700
Total fund balances	7,963,445	5,011,881
TOTAL	8,305,227	5,710,591

These figures, as presented, represent a summary of the financial statements of UICC. A complete set of the audited financial statements for 2013 may be obtained on request from the UICC office in Geneva.

MANAGEMENT OF CONFLICT OF INTEREST

Four years ago, UICC's Board of Directors concluded that the ambitions of the organisation were best served by working with, and across, a large number of partners drawn from UN agencies, international organisations, civil society, academia and the private sector. They recognised that such a strategy had the potential to create real or perceived conflicts of interest and therefore sought to minimise and manage such circumstances by developing internal policies, ensuring that the organisation was diligent in its partnership recruitment and development.

UICC considers that partnerships form a significant role in the implementation of its purpose and its long-term strategic objectives. We believe that action against cancer on a global scale demands the full engagement of a wide range of willing and committed partners. Our partnerships are based on clarity of purpose, mutual respect and a shared commitment to contribute positively to the purpose of UICC and its business priorities.

Our partnerships are bound by formal partnership agreements, which set out the nature of the relationship, the work which we jointly undertake and how funds will be used by the UICC team and its collaborators. Most of the partnership agreements are long-term in nature and they are reviewed on an annual basis by the UICC management team and the Board of Directors. All the partnerships contribute to the delivery of UICC's business plan, which is reviewed and agreed to by UICC's Board of Directors on an annual basis.

The Board of Directors also oversees how we develop the partnership portfolio and reviews the UICC sponsorship policy on an annual basis. The current version of the sponsorship policy for UICC can be found at www.uicc.org/partners/strategic-documents.

It is worth noting that UICC will neither accept funds from any organisation which promotes unhealthy behaviour, nor will it engage in dialogue with organisations with activities related to tobacco, alcohol or other carcinogenic products.

Wherever possible, UICC secures unrestricted funding to support the core business activity, but there are occasions when restricted funding is secured for projects and programmes which are integral to the UICC business plan and align closely with the priorities of the partner.

WORKING IN PARTNERSHIP

To address the increasing worldwide cancer burden and achieve sustainable development goals at strategic and operational levels in a globally inter-connected world, UICC has adopted a multi-sectoral partnership approach, engaging with governments, civil society and the private sector.

Each strategic partnership operates within a series of agreed ground rules and shared principles based on equity, transparency and mutual benefit. This code of conduct guarantees UICC's independence, integrity and objectivity. Our status of 'trusted advisor' enables UICC to activate a sense of common purpose among the global cancer community and support the delivery of the **World Cancer Declaration** targets, in-line with our purpose statement: **"We unite the cancer community to reduce the global cancer burden, to promote greater equity, and to integrate cancer control into the world health and development agenda."**

"UICC has a very clear operating model. As a partner we feel respected, involved, consulted and part of the agenda. Our views are considered and when appropriate, UICC includes us in the meetings in which we can have an impact."

**Jacqueline Godet, President,
French League Against Cancer**

DUTCH CANCER SOCIETY

Founded in 1949, the Dutch Cancer Society (DCS) is the Netherlands' largest cancer society and a member of UICC since 1982. The organisation focuses on prevention, education and training and patient support, financing an estimated 50% of the cancer research projects in the Netherlands and partnering with leading NGOs internationally.

Convinced that global collaboration is a prerequisite for progress in cancer control, DCS joined the UICC Champions Programme in 2011 to help UICC drive our global advocacy agenda, which resulted in landmark progress: the adoption of the UN Political Declaration on NCDs in 2011, followed by the Member States endorsement of the WHO Global Action Plan for the prevention and control of NCDs 2013-2020, the adoption of the Global Monitoring Framework on NCDs as well as the commitment to develop a Global Coordination Mechanism, including multi-sectoral engagement in the global NCD response.

Building on this global success and the high-impact results seen at a national level (the contributions of DCS have helped lead to a 60% increase in the overall five-year survival rate for Dutch cancer patients) the organisation announced an impressive multi-year pledge in 2012 to move other UICC projects forward at country and national levels, including: the Global Initiative for Cancer Registry (GICR) that UICC co-runs with the International Agency for Research on Cancer (IARC), and the Cervical Cancer Initiative (CCI) which involves multi-partnerships.

GICR aims to develop the capacity to produce reliable, high-quality information on the burden of cancer so that effective policies for cancer control may be developed, implemented and evaluated. So far, GICR has established three regional hubs covering South and East Asia, West and Central Asia, Sub-Saharan Africa and North Africa.

Our collaboration with DCS focused on Latin America to tackle the immense gap existing within the region. They have contributed to the development of a policy brief addressing the misconceptions about cancer registries in Latin America and helped establish a regional hub.

The Cervical Cancer Initiative (CCI) has the objective to significantly reduce the incidence and mortality of women dying from the disease through targeted and resourced interventions, especially in Latin America. To meet this goal, DCS and UICC have partnered to increase the access and use of cervical cancer services, by ensuring that civil society organisations working in womens' and youth health systematically integrate cervical cancer prevention into their existing services across Latin America and the Caribbean Region.

WORLD CANCER RESEARCH FUND INTERNATIONAL

World Cancer Research Fund International (WCRF International) leads and unifies a global network of cancer charities based in Europe, the Americas and Asia. Their leadership and expertise lies in the prevention and control of cancer by means of healthy food and nutrition, physical activity and body weight.

WCRF International has been a UICC member since 2005 and was one of the first partners of UICC's 'Together We Are Stronger' campaign, providing valuable input, promoting our messages and allocating significant financial contributions in support of our priority areas of activity. In particular, UICC and WCRF International have been working very closely in the global advocacy arena - leading working groups for the NCD Alliance - as well as in the development and preparation of the annual World Cancer Day campaigns, which most recently highlighted myths and misconceptions around cancer prevention and risk factors.

Drawing on their unique 'know-how' about key cancer risk factors, WCRF International has greatly contributed to the World Cancer Day campaign to increase outreach and public awareness, showing evidence of the existing connection between nutrition, physical activity and cancer, and releasing compelling data and reports. Their contribution helped to make the 2014 campaign a record-breaker, culminating in 8.7 billion opportunities to see, hear and read about World Cancer Day in the media.

"We support UICC because we believe in what they are trying to achieve, particularly in regards to cancer control plans. Every country should have a national cancer control plan and it should reflect the unique challenges being faced in that country. Our investment helps make this happen."

**Kathrin Kramis, CEO,
Swiss Cancer League**

VARIAN MEDICAL SYSTEMS AND ELEKTA

Varian Medical Systems and Elekta have invested in UICC as Vanguard partners over the last three years. They have provided expert commentary, personal engagement and financial commitment to help UICC achieve the priorities set out in its business plans. Varian Medical Systems focuses energy on saving lives, by equipping the world with advanced technology for fighting cancer and for X-ray imaging. Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders.

For many years, UICC has argued that radiotherapy treatment is an essential component in national cancer control planning. This commitment is embedded in the World Cancer Declaration Target 7: 'Improve access to services across the cancer care continuum', and UICC has advocated for treatment of cancer to be part of the non-communicable diseases (NCDs) discussions which have taken place on the global political stage. Together with many others, we were delighted to see that member states around the world committed to 'an 80% availability of the affordable basic technologies and essential medicines, including generics, required to treat major non-communicable diseases in both public and private facilities' as part of the Global Monitoring Framework for NCDs in May 2013.

UICC will continue to raise the profile of radiotherapy as a critical component of national cancer control planning in low- and middle-income countries. We intend to help Member States understand the costs and benefits of investing in radiotherapy and at the 2014 World Cancer Congress in Melbourne, we will release data showing the economic case for radiotherapy. Through our members in all countries, we will work to improve national capacity to deliver radiotherapy services via education and training.

"Unlike other NGOs, an investment in UICC makes a difference. The team are totally committed to making sure that our funds are used effectively in achieving objectives that we jointly agreed. I know that the impact we have is far greater than if we tried to do it ourselves."

Dow R. Wilson,
President and CEO, Varian

FONDATION PHILANTHROPIA

Fondation Philanthropia was created in 2008 by the Geneva-based Bank Lombard Odier & Co Ltd. It is an umbrella foundation and a registered Swiss charity which operates on behalf of private donors. Fondation Philanthropia is a grant-making foundation that works closely with operational partners like UICC. We are pleased to have worked on two projects with the foundation since 2011.

The Cervical Cancer Initiative (CCI): In El Salvador, UICC and its partner organisations have conducted a series of community-based training workshops for 500 participants and guided the Guatemalan Ministry of Health in the update of their national cervical cancer prevention guidelines, which will be released in 2014.

The Global Access to Pain Relief Initiative (GAPRI) seeks to make essential pain medicines universally available by 2025. The Fondation's financial support has helped UICC and its partners, including the American Cancer Society (ACS), to improve access to pain relief for those in need in Nigeria, one of the countries with the largest unmet need for pain relief in Sub-Saharan Africa. Through the ACS Treat the Pain programme, a contributor to GAPRI, we have provided 2.8 million additional days of pain treatment to the region, and raised the profile of the need for pain relief through international media and our advocacy campaigning. This has resulted in the World Health Assembly passing a Palliative Care Resolution in May 2014 setting out comprehensive commitments for Member States to address pain relief in their own countries.

"I appreciate the way in which UICC genuinely manages the conflict of interest issue. They are clear on how we can become involved in their initiatives and clear about when we cannot."

**Maria Pia Rufilli, Senior Director
International Public Affairs, Pfizer**

SANOFI AND THE SANOFI ESPOIR FOUNDATION

Sanofi and UICC have enjoyed a long-standing partnership, beginning in 2005 with the Sanofi Espoir Foundation (SEF) and My Child Matters (MCM), an international programme that addresses healthcare inequalities to improve survival rates for children with cancer in low-resource countries. Under the Foundation's leadership and financial support, and thanks to UICC's expertise in advocacy and training, 51 projects have been funded and operational in 33 countries to date.

My Child Matters is the world's leading childhood cancer programme and we anticipate to continue focusing on this issue to ensure that fewer children die unnecessarily from a disease, which in many cases, can be easily cured.

Since 2010, Sanofi has been a partner with UICC and the NCD Alliance, supporting both to deliver their ambitious advocacy objectives to secure cancer and other non-communicable diseases on the global health agenda. They have proved to be outstanding partners, willing to attend meetings in New York, Geneva and at the World Cancer Leaders' Summits in Dublin, Montréal and Cape Town and co-chair the NCD Alliance Supporters Group, which contributes to the thinking of the Alliance as it continues to grow and impact global health dialogues.



"We are proud to be one of UICC's leading partners and we applaud the organisation's efforts to unite the global cancer community. The UICC team is committed to including the industry perspective as one of many important voices across their major initiatives including World Cancer Day, the Leaders' Summit and Congress. Reducing the global cancer burden requires a multi-disciplinary approach and we congratulate UICC for helping to bring various stakeholders around the table to ultimately improve the outlook for people with cancer."

Brigitte Nolet, Head of Global Public Policy, Roche

REPORT OF THE AUDITOR ON THE 2013 FINANCIAL STATEMENTS



Report of the auditor
to the Board of Directors of
Union for International Cancer Control
Geneva

As statutory auditors, we have audited the financial statements of Union for International Cancer Control, which comprise the balance sheet, income statement and notes, for the year ended 31 December 2013.

Board of Directors' Responsibility

The Board of Directors is responsible for the preparation of the financial statements in accordance with the requirements of Swiss law and the company's articles of incorporation. This responsibility includes designing, implementing and maintaining an internal control system relevant to the preparation of financial statements that are free from material misstatement, whether due to fraud or error. The Board of Directors is further responsible for selecting and applying appropriate accounting policies and making accounting estimates that are reasonable in the circumstances.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Swiss Auditing Standards. Those standards require that we plan and perform the audit to obtain reasonable assurance whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers the internal control system relevant to the entity's preparation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the existence and effectiveness of the entity's internal control system. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of accounting estimates made, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements for the year ended 31 December 2013 comply with Swiss law and the company's articles of incorporation.

Report on other legal requirements

We confirm that we meet the legal requirements on licensing according to the Auditor Oversight Act (AOA) and independence (article 728 CO) and that there are no circumstances incompatible with our independence.

*PricewaterhouseCoopers Ltd, avenue Giuseppe-Motta 50, Case postale, CH-1211 Genève 2, Switzerland
Telephone: +41 58 792 91 00, Facsimile: +41 58 792 91 10, www.pwc.ch*

PricewaterhouseCoopers Ltd is a member of the global PricewaterhouseCoopers network of firms, each of which is a separate and independent legal entity.



In accordance with article 728a paragraph 1 item 3 CO and Swiss Auditing Standard 890, we confirm that an internal control system exists which has been designed for the preparation of financial statements according to the instructions of the Board of Directors.

We recommend that the financial statements submitted to you be approved.

PricewaterhouseCoopers SA

Philippe Tzaud
Audit expert
Auditor in charge

Louis Massicotte

Geneva, 10 April 2014

Enclosure:

- Financial statements (balance sheet, statement of support, revenue and expenses and changes in fund balances, statement of functional expenses and notes)

UICC PARTNERS

500k+

MEMBERS



250k+

MEMBERS



NON-MEMBERS



100k+

MEMBERS



Société canadienne du cancer



ligue suisse contre le cancer
lega svizzera contro il cancro

NON-MEMBERS



50k+

MEMBERS



NON-MEMBERS



25k+

MEMBERS



Programme of Action for Cancer Therapy PACT



NON-MEMBERS





A MEMBERSHIP ORGANISATION
FIGHTING CANCER TOGETHER

UNION FOR INTERNATIONAL CANCER CONTROL
UNION INTERNATIONALE CONTRE LE CANCER
62 route de Frontenex, 1207 Geneva, Switzerland
Tel +41 (0)22 809 1811 Fax +41 (0)22 809 1810
Email info@uicc.org Website www.uicc.org